Anti-obesity agents

Details Anti-obesity agents Anti-obesity agents

2011-03-15

2011-03-15

Desai, Anand U (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000

Reexamination Certificate

active

07906482

ABSTRACT:
The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.

REFERENCES:
patent: 4206199 (1980-06-01), Fujino et al.
patent: 4251631 (1981-02-01), Simon
patent: 4423034 (1983-12-01), Nakagawa et al.
patent: 4462941 (1984-07-01), Lee et al.
patent: 4859604 (1989-08-01), Gould et al.
patent: 4935492 (1990-06-01), Lewicki et al.
patent: 5354900 (1994-10-01), Matsuo et al.
patent: 5449751 (1995-09-01), Forssmann
patent: 5493007 (1996-02-01), Burnier et al.
patent: 5580853 (1996-12-01), Sytkowski
patent: 5604203 (1997-02-01), Balasubramaniam
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5837247 (1998-11-01), Oppenhelm et al.
patent: 5840733 (1998-11-01), Krantz et al.
patent: 5843440 (1998-12-01), Pouletty et al.
patent: 5874408 (1999-02-01), Nayar
patent: 5876969 (1999-03-01), Fleer et al.
patent: 5877151 (1999-03-01), Pereira
patent: 5877204 (1999-03-01), Davison et al.
patent: 5942620 (1999-08-01), Krantz et al.
patent: 6063761 (2000-05-01), Jones et al.
patent: 6087375 (2000-07-01), Bridon et al.
patent: 6103233 (2000-08-01), Pouletty et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6165470 (2000-12-01), Becquart et al.
patent: 6197813 (2001-03-01), Hegenauer
patent: 6277583 (2001-08-01), Krantz et al.
patent: 6277863 (2001-08-01), Krantz et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6342225 (2002-01-01), Jones et al.
patent: 6403324 (2002-06-01), Krantz et al.
patent: 6437092 (2002-08-01), Ezrin et al.
patent: 6440417 (2002-08-01), Thibaudeau et al.
patent: 6500918 (2002-12-01), Ezrin et al.
patent: 6514500 (2003-02-01), Bridon et al.
patent: 6593295 (2003-07-01), Bridon et al.
patent: 6602981 (2003-08-01), Ezrin et al.
patent: 6610825 (2003-08-01), Ezrin et al.
patent: 6706892 (2004-03-01), Ezrin et al.
patent: 6818611 (2004-11-01), Altman
patent: 6849714 (2005-02-01), Bridon et al.
patent: 6887849 (2005-05-01), Bridon et al.
patent: 7033997 (2006-04-01), Forssmann et al.
patent: 7166695 (2007-01-01), Krantz et al.
patent: 2002/0018751 (2002-02-01), Bridon et al.
patent: 2003/0073630 (2003-04-01), Bridon et al.
patent: 2003/0105867 (2003-06-01), Colrain et al.
patent: 2003/0108568 (2003-06-01), Bridon et al.
patent: 2003/0170250 (2003-09-01), Ezrin et al.
patent: 2004/0106589 (2004-06-01), Webb et al.
patent: 2004/0127398 (2004-07-01), Bridon et al.
patent: 2004/0138100 (2004-07-01), Bridon et al.
patent: 2004/0156859 (2004-08-01), Ezrin et al.
patent: 2004/0248782 (2004-12-01), Bridon et al.
patent: 2005/0037974 (2005-02-01), Krantz et al.
patent: 2005/0065075 (2005-03-01), Erickson et al.
patent: 2005/0070475 (2005-03-01), Bridon et al.
patent: 2005/0176643 (2005-08-01), Bridon et al.
patent: 2006/0099571 (2006-05-01), Altman
patent: 2009/0175821 (2009-07-01), Bridon et al.
patent: 252539 (1987-12-01), None
patent: 19936780 (2001-02-01), None
patent: 19942230 (2001-03-01), None
patent: 0602290 (1994-06-01), None
patent: 0911034 (1999-04-01), None
patent: 1234586 (2002-08-01), None
patent: 03502691 (1989-08-01), None
patent: 03178998 (1991-08-01), None
patent: 9201476 (1992-02-01), None
patent: WO-93/25217 (1993-12-01), None
patent: 9422467 (1994-10-01), None
patent: WO-95/00534 (1995-01-01), None
patent: WO-95/10302 (1995-04-01), None
patent: WO-96/06626 (1996-03-01), None
patent: 9614854 (1996-05-01), None
patent: 9629342 (1996-09-01), None
patent: WO-96/28544 (1996-09-01), None
patent: WO-97/25074 (1997-07-01), None
patent: 9729372 (1997-08-01), None
patent: WO-97/29372 (1997-08-01), None
patent: WO-98/00171 (1998-01-01), None
patent: 9820885 (1998-05-01), None
patent: WO-99/24074 (1999-05-01), None
patent: WO-99/24075 (1999-05-01), None
patent: WO-99/24076 (1999-05-01), None
patent: WO-99/24462 (1999-05-01), None
patent: WO-99/48534 (1999-09-01), None
patent: WO-99/48536 (1999-09-01), None
patent: WO-00/69900 (2000-11-01), None
patent: WO-00/76550 (2000-12-01), None
patent: WO-00/76551 (2000-12-01), None
patent: 0117568 (2001-03-01), None
patent: 2004011498 (2004-02-01), None
patent: 2005099768 (2005-10-01), None
patent: 2005103087 (2005-11-01), None
patent: 2007049941 (2007-05-01), None
patent: 2007071068 (2007-06-01), None
patent: 2007085887 (2007-08-01), None
European Search Report mailed Nov. 15, 2005, for EP patent application No. EP20030771007.
Balasubramaniam A. et al., “Syntheses and Receptor Affinities of Partial Sequences of Peptide YY (PYY)”, Pept. Res. 1988 1, 32-35.
Balsubramaniam, A. et al., (2000) “Structure-Activity Studies Including a !(CH2-NH) scan of Peptide YY (PYY) Active Site, PYY(22-36), for Interaction with Rat Intestinal PYY Receptors: Development of Analogues with Potent in Vivo Activity in the Intenstine”, J. Med. Chem, 43, 3420-27.
Batterham, et al. “Gut Hormone PYY3-36 Physiology Inhibits Food Intake,” Nature 2002, 418, 650-4.
Bridon, et al., U.S. Appl. No. 09/623,533, filed Sep. 5, 2000, for “Long-Lasting Antiviral Fusion Inhibitor Peptide Conjugates Comprising BSA and DP-178”.
Bridon, et al., U.S. Appl. No. 09/623,543, filed Sep. 5, 2000, for “Long Lasting Anti-angiogenic Peptides”.
Costa et al., “Atrial Natriuretic Peptide Modifies Arterial Blood Pressure Through Nitric Oxide Pathway in Rats”, Hypertension 35:1119-1123, 2000.
Cruze et al., “The Y2 receptor mediates Increases in Collateral-Dependent Blood Flow in a Model of Peripheral Arterial Insufficiency”, Peptides, 28, pp. 269-280, 2007.
Decarr et al. “A Long-Acting Selective Neuropeptide Y2 Receptor PEGylated Peptide Agonist Reduces Food Intake in Mice”, Bioorganic & Medicinal Chemistry Letter, 17:1916-1919, 2007.
Eberlein et al., “A New Molecular Form of PYY: Structural Characterization of Human PYY (3-36) and PYY (1-36)”, Peptides, vol. 10, pp. 797-803, 1989.
Keire, et al. “Solution Structure of Monomeric Peptide YY Supports the Functional Significance of the PP-Fold”, Biochemistry, 2000, 39, 9935-9942.
Koskinen et al., “Synthesis of Alpha-Helix Substituted Analogs of Calcitonin Gene-Related Peptide”, Bioorganic & Medicinal Chemistry Letters 5(6):573-578, 1995.
Kratz, et al., “Albumin Conjugates of the Anticancer Drug Chlorambucil: Synthesis, Characterization, and In Vitro Efficacy”, Arch. Pharm. Pharm. Med. Chem., vol. 331, No. 2, pp. 47-53, 1998.
Kratz, et al., “Preparation, Characterization and In Vitro Efficacy of Albumin Conjugates of Doxorubicin”, Biol. Pharm. Bull., vol. 21, No. 1, pp. 56-61, 1998.
Kratz, et al., “Probing the Cysteine-34 Position of Endogenous Serum Albumin With Thiol-Binding Doxorubicin Derivatives. Improved Efficiency of an Acid-Sensitive Doxorubilin Derivative with Specific Albumin-Binding Properties Compared to that of the Parent Compound.” J. Med Chem. 2002, 45, 5523-33.
Nonaka et al., “Characterization of Blood-Brain Barrier Permeabililty to PYY 3-36, in the Mouse”, J. Pharmacol. Exp. Ther. 2003, 306, 948-53.
Schechter et al., “Reversible PEGylation of Peptide YY(3-36) Prolongs its Inhibition of Food Intake in Mice”, FEBS Letters 579:2439-2444 (2005).
Takagi et al., “Enhancement of the Thermostability of Subtilisin E by Introduction of A Disulfide Bond Engineered on the Basis of Structural Comparison with a Thermophilic Serine Protease”, J. Biol. Chem., vol. 265, No. 12, pp. 6874-6878, 1990.
Tatemoto, “Isolation and Characterization of Peptide YY (PYY), a Candidate Gut Hormone that Inhibits Pancreatic Exocrine Secretion”, Proc. Natl. Acad. Sci. USA, 79:25

Affiliated with

Also associated with

Rating

Anti-obesity agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-obesity agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-obesity agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2772408